SHANGHAI JUNSHI BIO YC1 (F:8SJ) — Stock Price
SHANGHAI JUNSHI BIO YC1 (F:8SJ) is currently trading at €2.12 EUR, down 0.93% today. Over the past 52 weeks, shares have ranged between €1.71 and €4.06. This page tracks SHANGHAI JUNSHI BIO YC1's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of SHANGHAI JUNSHI BIO YC1.
SHANGHAI JUNSHI BIO YC1 (8SJ) Stock Price Chart — Daily History & Trading Volume
The chart below tracks SHANGHAI JUNSHI BIO YC1's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
SHANGHAI JUNSHI BIO YC1 Income Statement — Revenue, Profit & Earnings by Year
SHANGHAI JUNSHI BIO YC1's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | €2.50 Billion | €1.95 Billion | €1.50 Billion | €1.45 Billion | €4.02 Billion |
| Cost of Revenue | €522.76 Million | €498.86 Million | €667.29 Million | €526.28 Million | €1.26 Billion |
| Gross Profit | €1.98 Billion | €1.45 Billion | €835.26 Million | €927.21 Million | €2.77 Billion |
| Research & Development | €1.38 Billion | €1.28 Billion | €1.94 Billion | €2.38 Billion | €2.07 Billion |
| SG&A | €1.57 Billion | €1.53 Billion | €1.40 Billion | €1.29 Billion | €1.38 Billion |
| Total Operating Expenses | €3.42 Billion | €3.25 Billion | €3.95 Billion | €4.17 Billion | €4.62 Billion |
| Operating Income | €-925.10 Million | €-1.30 Billion | €-2.45 Billion | €-2.72 Billion | €-592.71 Million |
| EBITDA | — | — | — | — | — |
| EBIT | — | — | — | — | — |
| Interest Expense | €74.77 Million | €51.35 Million | €29.01 Million | €29.37 Million | €21.83 Million |
| Income Before Tax | €-986.57 Million | €-1.36 Billion | €-2.49 Billion | €-2.68 Billion | €-592.65 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | €-840.91 Million | €-1.28 Billion | €-2.28 Billion | €-2.39 Billion | €-718.56 Million |
SHANGHAI JUNSHI BIO YC1 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes SHANGHAI JUNSHI BIO YC1's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | €12.40 Billion | €10.80 Billion | €11.36 Billion | €12.58 Billion | €11.05 Billion |
| Total Current Assets | €4.46 Billion | €4.28 Billion | €5.55 Billion | €7.20 Billion | €5.83 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €600.78 Million | €430.51 Million | — | — | — |
| Net Receivables | €506.44 Million | €509.82 Million | €479.72 Million | €232.72 Million | €1.29 Billion |
| Inventory | €573.11 Million | €584.47 Million | €538.05 Million | €599.02 Million | €484.60 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | €6.33 Billion | €4.85 Billion | €4.02 Billion | €2.78 Billion | €2.72 Billion |
| Total Current Liabilities | €2.81 Billion | €2.53 Billion | €2.48 Billion | €1.77 Billion | €2.02 Billion |
| Long-term Debt | €2.79 Billion | €1.98 Billion | €1.20 Billion | €839.58 Million | €490.00 Million |
| Net Debt | €1.46 Billion | €387.60 Million | — | — | — |
| Total Stockholder Equity | €6.05 Billion | €5.88 Billion | €7.17 Billion | €9.50 Billion | €7.96 Billion |
| Retained Earnings | €-11.16 Billion | €-10.32 Billion | €-9.04 Billion | €-6.76 Billion | — |
SHANGHAI JUNSHI BIO YC1 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how SHANGHAI JUNSHI BIO YC1 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | €-514.51 Million | €-1.44 Billion | €-2.01 Billion | €-1.78 Billion | €-641.90 Million |
| Capital Expenditures | €768.30 Million | €690.99 Million | €832.58 Million | €393.95 Million | €886.23 Million |
| Free Cash Flow | €-1.28 Billion | €-2.13 Billion | €-2.85 Billion | €-2.17 Billion | €-1.53 Billion |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | €77.15 Million | €0.00 | €22.98 Million | €91.91 Million | €192.75 Million |
| Depreciation | €280.50 Million | €283.88 Million | €303.22 Million | €293.65 Million | €262.56 Million |
| Change in Cash | €129.03 Million | €-1.30 Billion | €-2.23 Billion | €2.40 Billion | €142.83 Million |
SHANGHAI JUNSHI BIO YC1 Earnings History — EPS Actual vs. Analyst Estimates
Track SHANGHAI JUNSHI BIO YC1's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 26, 2026 | — | — | — |
| Apr 27, 2026 | — | — | — |
| Mar 13, 2026 | — | — | — |
| Oct 28, 2025 | — | — | — |